Medicenna Therapeutics (OTCMKTS:MDNAF) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Medicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01, Zacks reports.

Medicenna Therapeutics Stock Performance

OTCMKTS:MDNAF traded down $0.00 during mid-day trading on Tuesday, hitting $0.25. The company had a trading volume of 2,800 shares, compared to its average volume of 68,406. The business’s fifty day moving average is $0.30 and its two-hundred day moving average is $0.38. The firm has a market cap of $23.43 million, a P/E ratio of -1.59 and a beta of 2.09. Medicenna Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $1.30.

Medicenna Therapeutics Company Profile

(Get Free Report)

Medicenna Therapeutics is a Canadian biotechnology company focused on developing engineered cytokine-based immunotherapies for cancer. The company’s research centers on its “Superkine” platform, which is designed to modify cytokines—proteins involved in immune signaling—to direct immune activity toward tumors. Its development programs have included MDNA11, an engineered interleukin-2 designed to stimulate cancer-fighting T cells and natural killer cells, and MDNA55, an investigational treatment targeting receptors found on certain brain tumors.

See Also

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.